Original Title: Guide usage optimal: antibioprophylaxie lors des chirurgies orthopédiques propres chez l’enfant et l’adulte

Authors' objectives: In 2005, the Conseil du médicament (which is now an integral part of INESSS) published an optimal use guide (OUG) entitled “Antibioprophylaxie lors des chirurgies orthopédiques”. Since then, a number of learned societies and recognized organizations have published clinical practice guidelines (CPGs) on surgical site infection prevention or, more specifically, surgical antibiotic prophylaxis. In addition, in Québec, nosocomial infection prevention and control and the fight against antibiotic resistance are a ministerial action priority. INESSS therefore set out to update the Conseil du médicament’s guide so that the recommendations concerning antibiotic prophylaxis during orthopedic surgery reflect the latest scientific data and the recommended best practices. The objective of this report is to present all the data gathered and the recommendations developed as part of this project.

Authors' results and conclusions: RESULTS: Each section of the previous version of the guide was revised in light of the data obtained from the CPGs and the other relevant scientific publications, and of the contextual and experiential data. More specifically, these data led to the addition, deletion or modification of a number of recommendations in the 2005 version. For instance, the dosages of cefazoline recommended in adults are higher than those recommended in 2005. On the subject of vancomycin, the recommended dosage in adults is no longer a fixed dose but rather a dosage that depends on the patient’s specific weight. Furthermore, it is now recommended that antibiotic prophylaxis no longer be prolonged after surgical incision closure, even if there is a drain. The recommendation concerning the appropriate timing of administration, which was “at induction of anesthesia” in the 2005 version, has been replaced with a more specific recommendation concerning the interval of time to be considered in relation to the first surgical incision, although there is a lack of clinical studies with a high level of evidence on this topic. The recommendation regarding the most appropriate time to administer antibiotic prophylaxis in relation to tourniquet inflation has been deleted because of a lack of sufficient scientific evidence. Furthermore, the management of patients with a history of penicillin allergy is now explained according to the type and severity of the initially observed allergic reaction. Lastly, recommendations have been developed concerning S. aureus nasal carriage decolonization with 2% mupirocin ointment, whose use can, in adult carriers, be considered an additional measure aimed at reducing the S. aureus surgical site infection (SSI) rate. CONCLUSION: The clinical recommendations in the 2018 version of the OUG, which mainly concern the choice of antibiotic therapy and the details of administration, should help reduce the risk of surgical site infections associated with nonoptimal use of antibiotic prophylaxis during clean orthopedic surgery in adults and children.

Authors' methods: This update is based on the best available scientific data evaluated by the authors of the selected CPGs. A systematic literature review was conducted specifically to answer the question concerning the efficacy and safety of mupirocin when used for S. aureus nasal decolonization, and the question regarding the efficacy of antibiotic prophylaxis administered in the surgical cavity before incision closure. The scientific data were enhanced with the experiential knowledge provided by Québec health professionals who participated in this project and with contextual data specific to Québec. The scientific data were found by means of systematic searches in several literature databases (MEDLINE (PubMed), EMBASE (OvidSP), EBM Reviews and Cochrane) and in two registries of ongoing clinical trials (ClinicalTrials and the ICTRP (WHO)). The literature search was limited to items published between 2005 and 2018 in French or English. The websites of health technology assessment agencies and organizations, such as the Canadian Agency for Drugs and Technologies in Health (CADTH), the National Institute for Health and Care Excellence (NICE), France’s Haute Autorité de Santé (HAS) and the Scottish Intercollegiate Guidelines Network (SIGN) were consulted. CPGs were also searched for by consulting the Guidelines International Network (G-I-N), the National Guideline Clearinghouse (NGC) and the websites of organizations and learned societies, such as the American Academy of Orthopaedic Surgeons (AAOS), the Centers for Disease Control and Prevention (CDC), the Infectious Diseases Society of America (IDSA), the European Centre for Disease Prevention and Control (ECDC), the Surgical Infection Society (SIS), Enhanced Recovery After Surgery (ERAS), the American Society of Health-System Pharmacists (ASHP) and the World Health Organization (WHO). The reference lists in the publications selected were searched for other relevant items.

Project Status: Completed

URL for project: https://www.inesss.qc.ca/outils-cliniques/outils-cliniques/outils-par-types/aide-a-la-decision-dialogue-patient-aide-memoire-appropriation/outils/antibioprophylaxie.html#c6668

Year Published: 2018

URL for published report: https://www.inesss.qc.ca/outils-cliniques/outils-cliniques/outils-par-types/aide-a-la-decision-dialogue-patient-aide-memoire-appropriation/outils/antibioprophylaxie.html#c6668

English language abstract: An English language summary is available

Publication Type: Other

Country: Canada

Province: Quebec

Organisation Name: Institut national d'excellence en sante et en services sociaux

Contact Address: L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369

Contact Name: demande@inesss.qc.ca

Contact Email: demande@inesss.qc.ca

Copyright: L'Institut national d'excellence en santé et en services sociaux (INESSS)